KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 80 filers reported holding KEROS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $164,000 | -20.4% | 5,123 | -0.2% | 0.00% | – |
| Q2 2023 | $206,000 | +102.0% | 5,135 | +114.7% | 0.00% | – |
| Q1 2023 | $102,000 | -28.7% | 2,392 | -19.3% | 0.00% | – |
| Q4 2022 | $143,000 | +694.4% | 2,965 | +519.0% | 0.00% | – |
| Q3 2022 | $18,000 | +80.0% | 479 | +34.6% | 0.00% | – |
| Q2 2022 | $10,000 | -85.1% | 356 | -71.2% | 0.00% | – |
| Q1 2022 | $67,000 | -68.8% | 1,235 | -66.4% | 0.00% | – |
| Q4 2021 | $215,000 | +277.2% | 3,676 | +156.5% | 0.00% | – |
| Q3 2021 | $57,000 | +16.3% | 1,433 | +22.6% | 0.00% | – |
| Q2 2021 | $49,000 | -38.0% | 1,169 | -8.9% | 0.00% | – |
| Q1 2021 | $79,000 | +154.8% | 1,283 | +187.7% | 0.00% | – |
| Q4 2020 | $31,000 | +675.0% | 446 | +341.6% | 0.00% | – |
| Q3 2020 | $4,000 | 0.0% | 101 | +1.0% | 0.00% | – |
| Q2 2020 | $4,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |